DERM
Journey Medical Corporation NASDAQ Listed Nov 12, 2021$6.22
+5.07%
vs $5.92
Mkt Cap $152.4M
52w Low $4.39
37.6% of range
52w High $9.26
50d MA $5.65
200d MA $7.13
P/E (TTM)
-13.2x
EV/EBITDA
—
P/B
4.8x
Debt/Equity
0.0x
ROE
-35.9%
P/FCF
-12.2x
RSI (14)
47.80
ATR (14)
$0.30
Beta
1.04
50d MA
$5.65
200d MA
$7.13
Avg Volume
269.6K
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant acne; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Ximino, an oral minocycline drug for the treatment of moderate to severe acne; and Exelderm cream and solution for topical use. It also sells doxycycline hyclate tablets, minocycline hydrocholoride capsules, and sulconazole nitrate cream and solution. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.
9237 East Via de Ventura Boulevard · Scottsdale, AZ 85258 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 25, 2026 | AMC | -0.06 | -0.04 | +33.3% | 6.83 | -13.6% | -30.0% | -4.2% | -4.1% | +6.8% | -1.1% | — |
| Nov 12, 2025 | AMC | -0.08 | -0.09 | -12.5% | 9.08 | -3.6% | -15.3% | +2.6% | -2.5% | +3.4% | -3.8% | — |
| Aug 12, 2025 | AMC | -0.07 | -0.16 | -128.6% | 8.54 | -13.2% | -15.1% | +0.1% | -4.3% | +0.7% | +1.0% | — |
| May 14, 2025 | AMC | -0.24 | -0.18 | +25.0% | 5.97 | +4.5% | +18.9% | -2.3% | -2.7% | +1.9% | -1.5% | — |
| Mar 26, 2025 | AMC | -0.22 | 0.08 | +136.4% | 6.14 | +1.0% | -3.6% | +3.2% | -3.4% | +1.2% | +4.5% | — |
| Nov 12, 2024 | AMC | -0.17 | -0.12 | +29.4% | 5.45 | +0.9% | -6.1% | -0.8% | +1.6% | -2.1% | +5.9% | — |
| Aug 12, 2024 | AMC | -0.15 | -0.17 | -13.3% | 4.22 | +3.3% | +14.2% | -1.2% | -4.2% | -2.9% | +3.2% | — |
| May 13, 2024 | AMC | -0.26 | -0.53 | -103.8% | 3.57 | -3.4% | +1.1% | -0.6% | +0.8% | -4.7% | -1.4% | — |
| Mar 21, 2024 | AMC | -0.08 | -0.12 | -50.0% | 3.82 | -8.4% | -13.6% | -11.5% | +26.4% | +5.4% | -5.4% | — |
| Nov 7, 2023 | AMC | -0.15 | 0.80 | +633.3% | 3.43 | +9.3% | +9.6% | -2.1% | +1.4% | +6.4% | +1.3% | — |
| Aug 8, 2023 | AMC | -0.34 | -0.46 | -35.3% | 2.40 | +0.0% | +1.7% | -8.2% | +0.0% | -2.7% | -3.2% | — |
| May 22, 2023 | AMC | -0.44 | -0.57 | -29.5% | 1.42 | -2.8% | -12.7% | +0.0% | -10.5% | -4.5% | +8.5% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.83 | $5.90 | -13.6% | -30.0% | -4.2% | -4.1% | +6.8% | -1.1% |
| Aug 13 | Lake Street | Maintains | Buy → Buy | — | $8.54 | $7.41 | -13.2% | -15.1% | +0.1% | -4.3% | +0.7% | +1.0% |
| Jul 30 | B. Riley Securities | Maintains | Buy → Buy | — | $7.59 | $7.64 | +0.7% | +0.0% | -3.2% | -4.9% | +2.1% | +1.0% |
| Sep 7 | B. Riley Securities | Maintains | Buy → Buy | — | $2.51 | $2.41 | -4.0% | +3.6% | +13.5% | -3.1% | -7.0% | -2.3% |
| Jul 12 | B. Riley Securities | Maintains | Buy → Buy | — | $2.36 | $2.49 | +5.5% | -12.3% | -14.5% | +1.1% | +1.1% | +2.2% |
| May 23 | B. Riley Securities | Maintains | Buy → Buy | — | $1.42 | $1.38 | -2.8% | -12.7% | +0.0% | -10.5% | -4.5% | +8.5% |
No insider trades available.
8-K · 8.01
!! High
Journey Medical Corporation -- 8-K 8.01: Material Event / Announcement
Journey Medical's Emrosi secured expanded pharmacy benefit coverage, potentially increasing patient access and sales for its rosacea treatment.
Apr 21
8-K
Unknown — 8-K Filing
Journey Medical's earnings call today signals management confidence in discussing 2025 results, but investors should monitor whether revenue growth justifies the dermatology-focused commercial strategy amid competitive pressures.
Mar 25
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Tang Capital Management Llc | 1,854,596 | $14M | — | Dec 2025 |
| 2 | Wasatch Advisors Lp | 2,133,370 | $10M | Added | Mar 2026 |
| 3 | Opaleye Management Inc. | 975,000 | $8M | — | Dec 2025 |
| 4 | Vanguard Capital Management Llc | 1,082,080 | $5M | New | Mar 2026 |
| 5 | Ubs Group Ag | 390,138 | $2M | Added | Mar 2026 |
| 6 | Millennium Management | 383,067 | $2M | Reduced | Mar 2026 |
| 7 | Renaissance Technologies Llc | 242,500 | $1M | Reduced | Mar 2026 |
| 8 | American Financial Group Inc | 180,000 | $844K | — | Mar 2026 |
| 9 | Northern Trust Corp | 149,978 | $703K | Added | Mar 2026 |
| 10 | Vanguard Portfolio Management Llc | 122,245 | $573K | New | Mar 2026 |
| 11 | Morgan Stanley | 53,000 | $409K | Added | Dec 2025 |
| 12 | Frec Markets, Inc. | 50,500 | $237K | New | Mar 2026 |
| 13 | Bank Of New York Mellon Corp | 37,195 | $174K | Added | Mar 2026 |
| 14 | Bank Of America Corp /de/ | 32,206 | $151K | Added | Mar 2026 |
| 15 | Prelude Capital Management, Llc | 29,894 | $140K | New | Mar 2026 |
| 16 | Gladstone Institutional Advisory Llc | 26,571 | $125K | Reduced | Mar 2026 |
| 17 | Sjs Investment Consulting Inc. | 15,000 | $116K | — | Dec 2025 |
| 18 | Nuveen, Llc | 24,034 | $113K | Added | Mar 2026 |
| 19 | Jane Street Group, Llc | 13,957 | $108K | New | Dec 2025 |
| 20 | Focus Partners Wealth | 18,975 | $89K | Reduced | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$152.4M
Enterprise Value
$128.3M
P/E (TTM)
-13.23x
Forward P/E
85.79x
PEG Ratio
0.48x
P/B
4.78x
P/S
2.46x
P/FCF
-12.25x
EV/EBITDA
—
Shares Out
24.5M
Financials (TTM)
Revenue
$61.9M
Net Income
-$11.4M
EBITDA
-$3.8M
Free Cash Flow
-$12.4M
Op Cash Flow
-$12.4M
EPS Basic
$-0.47
EPS Diluted
$-0.47
EPS Forward
$0.07
Gross Margin
59.3%
Op Margin
-13.2%
Net Margin
-18.5%
Balance Sheet
Total Assets
$94.6M
Total Liab.
$62.7M
Total Equity
$31.9M
Cash
$24.1M
LT Debt
$18K
Book Value/Sh
$1.30
Debt/Equity
0.00x
Current Ratio
1.79
Quick Ratio
1.53
Returns & Growth
ROE
-35.9%
ROA
-12.1%
ROIC
-14.3%
Rev Growth YoY
+10.2%
EPS Growth YoY
+34.7%
Price Returns
2W
-0.6%
1M
+22.5%
3M
-22.8%
6M
-21.8%
12M
-21.7%
Technicals
52W High
$9.26
52W Low
$4.39
50d MA
$5.65
200d MA
$7.13
RSI (14)
47.80
ATR (14)
$0.30
Beta
1.04
Avg Volume
270K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$11.75
High
$13.00
Low
$10.50
Median
$11.75
Data updated apr 25, 2026 4:57am
· Source: financialmodelingprep.com